Marrone Bio Innovations

Marrone Bio Innovations, Inc., a biopesticide company, engages in the discovery, development, and marketing of natural products for weed, pest, and plant disease management. Its products include Regalia, a product that protects food and ornamental crops from fungal and bacterial diseases; GreenMatch EX, a post-emergence herbicide for burndown weed control for organic growers; and GreenMatch, a burndown herbicide that controls various annual and perennial weeds. The company also offers insecticides, herbicides, and products for controlling invasive zebra and quagga mussels in waterways. In addition, it finds naturally occurring microorganisms from habitats and develops them into products for controlling insects, weeds, nematodes, and plant diseases. The company provides its products online. Marrone Bio Innovations, Inc. was founded in 2006 and is based in Davis, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bioceres Crop Solutions Corp

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions completes merger with Madrone Bio, creating a global leader in sustainable agricultural solutions

Bioceres Crop Solutions Completes Merger With Marrone Bio, Creating a Global Leader in Sustainable Agricultural Solutions

RALEIGH, N.C., July 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI) announced that during a special shareholder meeting held on July 8, 2022, its shareholders approved a proposal to adopt the previously announced Agreement and Plan of Merger (Merger Agreement), dated as of March 16, 2022, by and among Bioceres Crop Solutions Corp. (BIOX), BCS Merger Sub, Inc., and MBI, pursuant to which MBI will be acquired by BIOX. At the special meeting, MBI's stockholders approved the adoption of the Merger Agreement and approved on a non-binding advisory basis certain executive compensation that may be paid or become payable in connection with the merger contemplated by the Merger Agreement. The final voting results for each proposal voted on at the special meeting will be set forth in a Form 8-K filed by MBI with the U.S. Securities and Exchange Commission.

Marrone Bio Innovations, Inc. Shareholders Approve Merger Agreement with Bioceres Crop Solutions Corp.

Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.

Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1

Marrone Bio Innovations, Inc. (NASDAQ:MBII ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Kevin Helash – Chief Executive Officer Linda Moore – Chief Legal Officer LaDon Johnson – Interim Chief Financial Officer Matti Tiainen – Senior Vice President International Sales Kamal El Mernissi – Senior Director of Product & Marketing Conference Call Participants Dmitry Silversteyn – Water Tower Research Operator Good afternoon ladies and gentlemen, and welcome to the First Quarter 2022 Earnings conference call. At this time all participants are in a listen-only mode.

Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q1 2022 Results - Earnings Call Transcript

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates

RALEIGH, N.C., May 11, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the first quarter ended March 31, 2022. Key results include:

Marrone Bio Innovations, Inc. Reports First-Quarter 2022 Financial Results

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates

Marrone Bio Innovations, Inc. (MBII) CEO Kevin Helash on Q4 2021 Results - Earnings Call Transcript

RALEIGH, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the fourth quarter and full year ended December 31, 2021. Key results include:

Marrone Bio Innovations, Inc. Reports Fourth-Quarter and Full-Year 2021 Financial Results

Company poised for continued growth in a $6+ billion market¹ Company poised for continued growth in a $6+ billion market¹

Marrone Bio Expands Biological Seed Treatment Collaboration for Row Crops

Agriforce Growing Systems Ltd

Arcadia Biosciences

S&W Seed

Farming & Agriculture Penny Stocks To Watch Right Now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Agriculture & Farmings Stocks To Watch

Wilmington, Delaware--(Newsfile Corp. - March 21, 2022) - Rigrodsky Law, P.A. is investigating Marrone Bio Innovations, Inc. ("Marrone") (NASDAQ: MBII) regarding possible breaches of fiduciary duties and other violations of law related to Marrone's agreement to be acquired by Bioceres Crop Solutions Corp. ("Bioceres") (NASDAQ: BIOX). Under the terms of the agreement, Marrone's shareholders will receive 0.088 shares of Bioceres common stock for each share of Marrone common stock they own.To learn more about this...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Marrone Bio Innovations, Inc. Merger

Today, a big merger announcement has prompted investors to pile into Marrone Bio Innovations and MBII stock, as this stock surges 50%. The post Why Is Marrone Bio Innovations (MBII) Stock Up Today?

Why Is Marrone Bio Innovations (MBII) Stock Up Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Marrone Bio Innovations, Inc. (NASDAQ: MBII) to Bioceres Crop Solutions Corp. is fair to Marrone Bio shareholders. Under the terms of the proposed transaction, each share of Marrone Bio common stock will be exchanged at closing for ordinary shares of Bioceres at a fixed ratio of 0.088. Halper Sadeh encourages Marrone Bio shareholders to click here to learn more about their legal

Marrone Bio (MBII) Stock Alert: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Marrone Bio Innovations, Inc. Is Fair to Shareholders

ROSARIO, Argentina & RALEIGH, N.C.--(BUSINESS WIRE)--Bioceres Crop Solutions and Marrone Bio Announce Merger Agreement

Bioceres Crop Solutions and Marrone Bio Announce Merger Agreement

RALEIGH, N.C., March 08, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, will release financial results for the fourth quarter and full year ended December 31, 2021, after market close on Monday, March 28, 2022.

Marrone Bio Innovations to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28 at 4:30 p.m. Eastern Time

RALEIGH, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, announced today a transition of its Chief Financial Officer role. Current CFO Sue Cheung has chosen to resign for personal reasons, effective March 9, 2022. LaDon Johnson, a director with CFO Systems, has been appointed interim CFO on a consulting basis while the company begins a national search for a permanent CFO.

Marrone Bio Announces CFO Transition

Announces Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results Announces Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results

Marrone Bio Innovations Issues Shareholder Letter

Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.

Marrone (MBII) Expands the Existing Inventory Line of Credit

RALEIGH, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) has expanded its existing inventory line of credit to support the company's expectations for growth in sales and manufacturing capacity. Under an amended agreement with LSQ Funding Group, L.C., the company can access a maximum of $4.5 million to finance inventory needs, up from $3 million under a prior agreement.

Marrone Bio's Inventory Line of Credit Increased to Support Sales and Manufacturing Growth

Supports Growth Plans in European and Latin American markets Supports Growth Plans in European and Latin American markets

Marrone Bio Relocates Corporate Headquarters to Raleigh, North Carolina

DAVIS, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- During November and December 2021, certain warrant holders in  Marrone Bio Innovations, Inc. (NASDAQ: MBII) completed the exercise of the fifth and final tranche of warrants, generating a total of $3.5 million in cash during the fourth quarter of 2021 and increasing the company's outstanding shares by 4.7 million. With these exercises, and the December 15, 2021, expiration of the substantial majority of the company's other unexercised warrants, the company's material warrant overhang has been eliminated.

Marrone Bio Warrant Holders Exercise Final Tranche, Eliminating Warrant Overhang

Estimated peak potential revenue for MBI-306 and its variants is $100 million Estimated peak potential revenue for MBI-306 and its variants is $100 million

Marrone Bio's Next-Generation Product for Environmentally Sustainable Pest Control Demonstrates Substantial Yield Gains in 2021 Field Trials

American Resources Corp

Foresight Autonomous Hlds

Gerdau

Esports Entertainment Group

ObsEva

Vertex Energy

These penny stocks remain positioned to run upwards in the near term. Purchasing shares in December could quickly lead to profits.

7 Hot Penny Stocks to Buy for December That Are Positioned to Pop

DAVIS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions published today their independent climate impact product assessment on Venerate® XC Bioinsecticide, scoring a 8.6 out of 10. The analysis evaluated the life-cycle inputs and impacts of Venerate XC per acre on the following: soil, aquatic and human toxicity, ecosystem impact, harmful materials, greenhouse gas (GHG) emissions and carbon return on investment (CROI).

News for Marrone Bio Innovations Stock (MBII)